Bispecifics Could Be A Threat To CAR-Ts, But Efficacy May Trump Convenience
Executive Summary
T-cell-engaging bispecific antibodies emerged at ASH as viable competitors for autologous T-cell therapies, but while their off-the-shelf availability is intriguing, it may be too early to say if their safety and efficacy beats CAR-Ts.
You may also be interested in...
ASH Data On CRS Helps Determine Where Anti-CD20 Bispecifics Fit Versus CAR-T
From the CD20-directed bispecific antibody studies presented at ASH, the risk and severity of cytokine release syndrome is being viewed as a way to determine whether the bispecifics will be used before, after or instead of CAR-Ts.
BMS Makes The Case For A Lasting Hematology Legacy
Bristol became a major hematology player through its acquisition of Celgene and it has a multi-pronged plan for maintaining its position as generics approach for Revlimid and other key products.
ASH Preview: Three Areas To Watch In Hematology-Oncology
Novartis hopes a CAR-T with rapid manufacturing will be a winner, while novel bispecific antibodies in lymphoma and myeloma will make appearances, along with next-generation PI3K and BTK inhibitors.